Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06314490 · ClinicalTrials.gov registry record · Phase 1
Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A
A Phase 1 study of Genetic Disease, sponsored by University of California, San Diego.
- Active
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT06314490: Active Phase 1 study of Genetic Disease, sponsored by University of California, San Diego.
NCT06314490 is a Phase 1 study of Genetic Disease that is active but no longer recruiting, run by University of California, San Diego. The registered enrollment target is 1 participants, below the 2,561-participant average among 30 other Genetic Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06314490, a Phase 1 study of Genetic Disease, is active but no longer recruiting, sponsored by University of California, San Diego.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single pediatric participant with SCN2A associated developmental epileptic encephalopathy
Conditions Studied
Interventions
- DRUG nL-SCN2A-002
Study Locations (1)
California
- Rady Children's Hospital - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-02-16 |
| Est. Completion | 2026-02-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06314490
The ClinicalTrials.gov registry entry for NCT06314490 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,561-participant average among 30 other Genetic Disease trials with a reported enrollment target (100% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Genetic Disease appearing as the primary indexed condition, and to 1 intervention - of which nL-SCN2A-002 is the first listed.
NCT06314490 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06314490 about?
NCT06314490 is a clinical study titled "Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A". This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single pediatric participant with SCN2A associated developmental epileptic encephalopathy
What is the current status of trial NCT06314490?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2024-02-16. Estimated completion is 2026-02-16.
What conditions does trial NCT06314490 study?
This clinical trial studies the following conditions: Genetic Disease.
What interventions are being tested in trial NCT06314490?
The interventions under investigation include: nL-SCN2A-002 (DRUG).
Who is sponsoring clinical trial NCT06314490?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06314490 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-label, Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for TUBB4A-related Leukodystrophy
ACTIVE NOT RECRUITING · Phase 1
-
An Adaptive Clinical Trial of BeginNGS Newborn Screening for Hundreds of Genetic Diseases by Genome Sequencing
RECRUITING · NA
-
Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome
RECRUITING
-
Rett Syndrome Registry
RECRUITING
-
Natural History Study of Patients with HPDL Mutations
RECRUITING
-
Diagnostic Odyssey: Whole Genome Sequencing (WGS)
RECRUITING
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.